Considering the importance of CD38 expression in MM, radiolabeled and fluorescence conjugates of daratumumab have been tested in preclinical models and patients.[13, 14, 15, 16, 17, 18, 19, 20, 21] Several clinical trials are ongoing to capture the heterogeneity in CD38 levels in the whole body using radiolabeled analogs of the FDA approved anti‐CD38 antibodies (mAbs). The gene discussed is CD38; the disease is Miyoshi myopathy.